Mitochondrial protective effects caused by the administration of mefenamic acid in sepsis

Diogo Dominguini1, Monique Michels2, Leticia B Wessler3

  • 1Laboratory of Experimental Pathophysiology, Graduate Program in Health Sciences, University of Southern Santa Catarina (UNESC), Criciúma, SC, 88806-000, Brazil. diogo_dominguini@unesc.net.

Insights

Mefenamic acid (MFA) protects the brain during sepsis by reducing inflammation and mitochondrial damage. This study shows MFA treatment decreases inflammatory markers and oxidative stress, preserving neuronal function in a sepsis model.

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Sepsis can lead to central nervous system dysfunction through inflammation and mitochondrial damage.
  • NOD-type receptor containing the pyrin-3 domain (NLRP-3) inflammasome activation and 8-oxoguanine (8-oxoG) accumulation in mitochondrial DNA (mtDNA) are implicated in sepsis-induced neuroinflammation and neuronal death.
  • Mefenamic acid (MFA) is known to inhibit inflammasome activity.

Purpose of the Study:

  • To investigate the neuroprotective effects of MFA in a polymicrobial sepsis model.
  • To evaluate MFA's impact on inflammatory parameters, oxidative stress, and mitochondrial damage in the brain during sepsis.
  • To determine if MFA administration can attenuate sepsis-induced neuronal dysfunction and apoptosis.

Main Methods:

  • Adult male Wistar rats underwent cecal ligation and perforation (CLP) to induce sepsis.
  • Rats received MFA (10, 30, or 50 mg/kg) or saline intravenously.
  • Brain tissues (frontal cortex, hippocampus) were analyzed 24 hours post-CLP for cytokine levels, oxidative damage markers, protein expression (NLRP-3, TFAM, 8-oxoG, apoptosis markers, IBA-1), and mitochondrial respiratory chain complex activity.

Main Results:

  • Sepsis induced increased pro-inflammatory cytokines (TNF-α, IL-1β, IL-18) via NLRP-3 activation, elevated oxidative damage (TBARS, carbonyl, DCF-DA), and increased 8-oxoG in mtDNA, alongside decreased TFAM and NGF-1 levels.
  • Septic rats exhibited higher levels of pro-apoptotic proteins and microglial activation (IBA-1 positive cells).
  • MFA treatment (30 and 50 mg/kg) significantly reduced inflammasome activity, inflammatory cytokines, oxidative stress, and 8-oxoG levels, while increasing TFAM, NGF-1, and Bcl-2 expression, thereby reducing microglial activation and improving mitochondrial function.

Conclusions:

  • MFA demonstrates significant neuroprotective effects in the early stages of sepsis.
  • MFA mitigates sepsis-induced neuroinflammation and mitochondrial dysfunction by inhibiting NLRP-3 inflammasome activation and reducing oxidative damage.
  • MFA treatment represents a potential therapeutic strategy to preserve central nervous system integrity during sepsis.